{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of High-Flow Nasal Oxygen vs. Laryngeal Mask Ventilation in Hysteroscopic Surgery"
      },
      "Trial_Design": {
        "score": 2,
        "evidence": "This single-center, randomized, noninferiority trial was conducted in a university hospital in Rome, Italy, from September 2022 to June 2023."
      },
      "Participants": {
        "score": 2,
        "evidence": "Eligible participants were ASA class I and II patients undergoing elective operative hysteroscopy."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomized 1:1 to receive either HFNO (70 L/min, 100% oxygen) or LMV (volume-controlled ventilation)."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial assessed whether HFNO is noninferior to laryngeal mask ventilation (LMV) in terms of intraoperative respiratory support success during 30-minute general anesthesia."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was intraoperative respiratory support success, defined as SpO2 \u2265 94% and tcCO2 < 65 mm Hg without rescue interventions."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomization was computer-generated, and allocation was concealed in sealed envelopes."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 180 patients were randomized (90 per group) and analyzed using an intention-to-treat approach."
      },
      "Number_Analysed": {
        "score": 2,
        "evidence": "A total of 180 patients were randomized (90 per group) and analyzed using an intention-to-treat approach."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "Intraoperative respiratory support was successful in 99% of patients in both groups (absolute difference 0, unilateral 95% CI, 3%, noninferiority P < .001)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Postoperative respiratory symptoms were significantly lower in the HFNO group (2% vs. 19%, P < .001)."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT05550584."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by Fisher and Paykel Healthcare."
      }
    },
    "total_score": 23,
    "max_score": 25
  },
  "model": "gpt-4o"
}